The FDA's application record carries an action on NDA 213871, Cibinqo (abrocitinib), sponsored by Pfizer. Abrocitinib is a selective JAK1 inhibitor licensed for atopic dermatitis, not an oncology drug, and this is a supplement to an existing approval rather than a new licence or a safety communication. The record does not say what the supplement covers.
It appears on an oncology desk because of the class. JAK inhibitors carry a boxed warning that includes malignancy, and the questions that reach oncologists are about patients with a cancer history who are offered one for an inflammatory skin or joint disease. That question is not answered by an application action, and it should not be answered from one.
What to do with it today is nothing, beyond noting it. When a dermatologist or rheumatologist asks whether a JAK inhibitor is safe in a patient with treated malignancy, the answer comes from the boxed warning and the individual cancer history, not from the FDA's daily application list. Abrocitinib's Indian regulatory position is not addressed in this record.
- Do not read an application action as a change to the boxed warning or to indications
- JAK inhibitor questions in cancer survivors need the label and the individual history, not a news item
- Check the current FDA label directly before advising a referring dermatologist or rheumatologist
- This record does not address abrocitinib's CDSCO status in India
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free